Provided by Tiger Fintech (Singapore) Pte. Ltd.

Omeros

8.42
+0.56007.12%
Post-market: 8.420.00000.00%16:23 EDT
Volume:373.07K
Turnover:3.12M
Market Cap:487.94M
PE:-3.71
High:8.54
Open:8.02
Low:7.94
Close:7.86
Loading ...

Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint

THOMSON REUTERS
·
16 Jan

Omeros Corp: Sensitivity Analyses Support Results of Primary Endpoint Analysis

THOMSON REUTERS
·
16 Jan

Omeros Corp - Plans to Resubmit to FDA Later This Quarter Bla for Narsoplimab

THOMSON REUTERS
·
16 Jan

Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint

Business Wire
·
16 Jan

When Can We Expect A Profit From Omeros Corporation (NASDAQ:OMER)?

Simply Wall St.
·
27 Dec 2024

retail investors who own 52% along with institutions invested in Omeros Corporation (NASDAQ:OMER) saw increase in their holdings value last week

Simply Wall St.
·
24 Dec 2024

Omeros initiated with a Buy at D. Boral Capital

TIPRANKS
·
23 Dec 2024

Sector Update: Health Care Stocks Lower Thursday Afternoon

MT Newswires Live
·
20 Dec 2024

Omeros Stock Gains 52% On Successful Trial Results

Dow Jones
·
19 Dec 2024

Omeros Reports Narsoplimab TA-TMA Trial Success; Stock Surges

GuruFocus.com
·
19 Dec 2024

Omeros Up Over 66%, On Track for Highest Close Since September 2021 -- Data Talk

Dow Jones
·
19 Dec 2024

Omeros' Pivotal Trial of Narsoplimab Meets Primary Endpoint

MT Newswires Live
·
19 Dec 2024

Omeros announces narsoplimab trial meets primary endpoint

TIPRANKS
·
19 Dec 2024

Omeros Corp: to Resubmit a Bla to FDA for Narsoplimab

THOMSON REUTERS
·
19 Dec 2024

Omeros' Narsoplimab Meets Its Pivotal Trial Primary Endpoint

THOMSON REUTERS
·
19 Dec 2024

Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA

Business Wire
·
19 Dec 2024